America’s top infectious disease expert Dr Anthony Fauci has said that he is cautiously optimistic over the results from the current clinical trials and the possibility of developing a vaccine for COVID-19 by the end of this year or early next year.
“The lessons we’ve learned from the coronavirus is they have pandemic potential, they’re likely to continue to emerge. Good public health measures are critical to controlling them”, he said.
“Global collaboration and transparency are critical if we are to get a containment of this extraordinary assault on the human population, a viral disease that spreads rapidly and as a high degree of morbidity and mortality,” he said in his recorded remarks during an online session on ‘Confronting COVID-19 Through Innovation and Research: Lessons Learned from the Pandemic’.
The event is part of a series of online dialogue by the United Nations Academic Impact (UNAI) dubbed ’75 for UN75: 75 Minutes of Conversation’.
Giving an overview of the pandemic and efforts to develop a vaccine, Fauci said: “we’ve adapted a strategic approach to get multiple candidates and there are more than one candidate vaccine to be conducted in trials in a harmonised way so that we use standard endpoints, standard and single data and safety monitoring board as well as identical immunological parameters that are measured, so that you could bridge one study to another.”
Fauci said “hopefully we’ll be able to get some information, such as with this particular one representative vaccine… that we started here in January. Phase one looks good, very promising data on the induction of neutralising antibody” and will go into trial at the end of July”.
There are 5-7 candidates that are going into clinical trials at different stages, he said. The Moderna coronavirus vaccine is showing promising results, “which makes me cautiously optimistic. Although you can never, ever predict with any certainty, whether a vaccine is going to be safe and effective. “The early data on these trials have a cautious optimism that we will be successful at least in developing a vaccine with some degree of efficacy by the end of the year, beginning of 2021,” he said.
Moderna has completed enrollment of Phase 2 Study of its mRNA vaccine against COVID-19. It has also finalised the Phase 3 study protocol based on the feedback from the US Food and Drug Administration (FDA).
America’s Top Infectious Disease Expert Fauci Cautiously Optimistic Over Covid-19 Vaccine Development By Early 2021
